Nyheder

Lundbeckfonden Ventures nyheder

Russell G. Greig Appointed as Chairman of SyntaxinOxford, UK, 6th January 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been appointed as Chairman with immediate effect. In joining Syntaxin, Dr. Greig brings with him over 30 years experience in the pharmaceutical industry,...
DBV Technologies closes $25.5 (?19,4) million Series ‘C’ financing round including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and ALTO Invest; as well as existing investors Sofinnova Partners and ALK AbelloProceeds will be used, for the most part, to further continue the clinical development of VIASKIN® Peanut, the world’s first epicutaneous skin patch for desensitization...
Lundbeckfond Ventures is LFÍ Life Science Investments new name
Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces it has successfully raised £18 million in new funding
Mette Kirstine Agger appointed Head of LFI Life Science Investments
1 45 46 47

Lundbeckfonden Ventures

Nyheder

Interview med Mette Kirstine Agger om bioteknologiens udvikling i Danmark og Europa
3. december 2018
DYSIS Medical Announces Appointment of New Chief Executive and Chief Commercial Officer
27. november 2018
Acacia Pharma Group PLC – ACACIA PHARMA ANNOUNCES POSITIVE BARHEMSYS(TM) RESCUE TREATMENT DATA PUBLISHED IN ANESTHESIOLOGY
21. november 2018